2-(3-Hydroxy-1-Adamantyl)-2-Oxoacetic Acid CAS 709031-28-7 Purity >99.0% (HPLC)

Short Description:

Name: 2-(3-Hydroxy-1-Adamantyl)-2-Oxoacetic Acid

Synonyms: 3-Hydroxy- α-Oxoadamantane-1-Acetic Acid

CAS: 709031-28-7

Purity: >99.0% (HPLC)

Appearance: White to Off-White Crystal Powder

Intermediate of API (CAS: 361442-04-8)

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Related Intermediates
CAS 361442-04-8
CAS 945667-22-1
(R)-1-Boc-3-Aminopiperidine CAS 188111-79-7
(R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4
Boc-3-Hydroxy-1-Adamantyl-D-Glycine CAS 361442-00-4
(1S,3S,5S)-3-(Aminocarbonyl)-2-Azabicyclo [3.1.0]hexane-2-Carboxylic Acid tert-Butyl Ester CAS 361440-67-7
2-(3-Hydroxy-1-Adamantyl)-2-Oxoacetic Acid CAS 709031-28-7

Chemical Properties:

Chemical Name	2-(3-Hydroxy-1-Adamantyl)-2-Oxoacetic Acid
Synonyms	3-Hydroxy- α-Oxoadamantane-1-Acetic Acid; 2-(3-Hydroxyadamantan-1-yl)-2-Oxoacetic Acid; 3-Hydroxy-α-Oxotricyclo[3.3.1.13,7]decane-1-Acetic Acid
CAS Number	709031-28-7
CAT Number	RF-PI2288
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C12H16O4
Molecular Weight	224.26
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Off-White Crystal Powder (Visual)
Identification HPLC	The Retention Time of Major Peak Obtained from Sample Solution is Correspond to Reference Standard
Melting Point	162.0~166.0℃
Water (by Karl Fischer)	<0.50% (USP<921>)
Purity / Analysis Method	>99.0% (HPLC)
Assay	98.0%~102.0% (On Dried Basis)
Test Standard	Enterprise Standard
Usage	Intermediate of API (CAS: 361442-04-8)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

2-(3-Hydroxy-1-Adamantyl)-2-Oxoacetic Acid (CAS: 709031-28-7) is an intermediate of API (CAS: 361442-04-8), which is a type 2 diabetes drug that can stimulate the pancreas to produce more insulin after the meal. It was reached by the cooperation of AstraZeneca and Bristol-Myers Squibb Company and belongs to DPP-IV inhibitor. It plays the role through inhibiting GLP-l degradation. GLP-I is the hormones naturally produced in the intestine after taking food. It can regulate the secretion of insulin and strengthen the utilization of glucose in the peripheral tissues.